Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
Ivor Elrifi, CEO of Tiziana Life Sciences, expressed enthusiasm about this milestone, stating, "We are excited to initiate this important clinical study with the support of the ALS Association grant.
Tiziana Life Sciences Ltd.: Tiziana Life Sciences Files Investigational New Drug Application with FDA for ALS Phase 2 Clinical Trial
NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...
Tiziana Life Sciences files IND application with FDA for ALS Phase 2 trial
Tiziana Life Sciences (TLSA) announced the submission of its Investigational New Drug, IND, application to the U.S. Food and Drug ...
BioNTech stock falls after FDA clinical hold on malaria vaccine trial
The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...
BioNTech SE's RNA-based vaccine for malaria placed on clinical hold by FDA
BioNTech SE (NASDAQ:BNTX) said on Tuesday, that the U.S. Food and Drug Administration informed of a clinical hold on the ...
manilatimes13h
Quoin Pharmaceuticals Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications
Proprietary Invisicare Delivery Technology Designed to Optimize Local Skin Penetration The proprietary Invisicare delivery technology, which Quoin has exclusive rights to for all orphan rare skin ...
Tiziana Life Sciences ticks up on IND submission for mid-stage trial of its ALS treatment
Tiziana Life Sciences (NASDAQ:TLSA) rises after the company said it is planning the submission of its Investigational New ...
manilatimes19h
ONWARD Medical to Advance Parkinson's Disease Pipeline with Support from The Michael J. Fox Foundation and US Department of Defense
The Michael J. Fox Foundation for Parkinson's Research is supporting a study addressing mobility challenges in Parkinson's ...
Nature14h
KDDF bolsters the development of innovative cancer therapies
PimedBio recently submitted an investigational new drug (IND) application for PMB212. AbTis: overcoming limitations of antibody–drug conjugate linkers AbTis, founded in 2016 and acquired by Dong ...
clinicaladvisor.com11h
FDA Fast Tracks Investigational Nonopioid Treatment for Acute Pain
LTG-001, a selective inhibitor for treatment of acute pain, was granted Fast Track designation by the Food and Drug Administration (FDA).
How AI Could Revolutionize Drug Development and Save Billions
BullFrog AI plans to introduce what it considers a game-changing approach that could shorten timelines, reduce costs, and ...
WebMD8h
FDA Approves New Treatment for Stroke
The FDA has approved TNKase, a new, fast-acting stroke treatment that dissolves blood clots more efficiently, marking a significant advancement in stroke therapy and clot-busting technology.